Evaluation of a bivalent (CVD 103-HgR CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru

被引:38
作者
Taylor, DN
Tacket, CO
Losonsky, G
Castro, O
Gutierrez, J
Meza, R
Nataro, JP
Kaper, JB
Wasserman, SS
Edelman, R
Levine, MM
Cryz, SJ
机构
[1] USN, MED RES INST DETACHMENT, LIMA, PERU
[2] CTR MED NAVAL, CALLAO, PERU
[3] UNIV MARYLAND, SCH MED, CTR VACCINE DEV, BALTIMORE, MD USA
[4] SWISS SERUM & VACCINE INST, CH-3001 BERN, SWITZERLAND
关键词
D O I
10.1128/IAI.65.9.3852-3856.1997
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To provide optimum protection against classical and El Tor biotypes of Vibrio cholerae O1, a single-dose, oral cholera vaccine was developed by combining two live, attenuated vaccine strains, CVD 103-HgR (classical, Inaba) and CVD 111 (El Tor, Ogawa), The vaccines were formulated in a double-chamber sachet; one chamber contained lyophilized bacteria, and the other contained buffer, In the first study, 23 U.S. adult volunteers received CVD 103-HgR at 10(8) CFU plus CVD 111 at 10(8), 10(7), or 10(6) CFU, CVD 111 alone at 10(7) CFU, or placebo, In the second study, 275 Peruvian adults were randomized to receive CVD 103-HgR at 10(9) CFU plus CVD 111 at 10(9) or 10(8) CFU, CVD 111 alone at 10(9) CFU, CVD 103-HgR alone at 10(9) CFU, or placebo, Three of 15 U.S. volunteers who received CVD 111 at 10(7) or 10(8) CFU developed mild diarrhea, compared to none of 4 who received CVD 111 at 10(6) CFU and 1 of 4 who received placebo, Twelve (63%) of 19 vaccine recipients shed the El Tor vaccine strain, All but one volunteer developed significant Ogawa and Inaba vibriocidal antibody titers, Volunteers who received CVD 111 at 10(7) CFU had geometric mean Ogawa titers four to five times higher than those of volunteers who received the lower dose, In the second study, all dosage regimens were well tolerated in Peruvians, About 20% of volunteers who received CVD 111 at the high dose excreted the El Tor organism, compared to 7% in the low-dose group, CVD 111 was detected in the stools of two placebo recipients, neither of whom had symptoms or seroconverted. In all vaccine groups, 69 to 76% developed fourfold rises in Inaba vibriocidal antibodies, Among those who received the bivalent vaccine, 53 to 75% also developed significant rises in Ogawa vibriocidal antibodies, We conclude that it is feasible to produce a single dose, oral bivalent vaccine that is safe and immunogenic against both biotypes (El Tor and classical) and both serotypes (Inaba and Ogawa) of cholera for populations in both developed and developing Darts of the world.
引用
收藏
页码:3852 / 3856
页数:5
相关论文
共 22 条
[1]  
[Anonymous], 1995, Lancet, V345, P339
[2]   DIAGNOSIS AND TREATMENT OF CHOLERA IN THE UNITED-STATES - ARE WE PREPARED [J].
BESSER, RE ;
FEIKIN, DR ;
EBERHARTPHILLIPS, JE ;
MASCOLA, L ;
GRIFFIN, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (15) :1203-1205
[3]   BIOTYPE AS DETERMINANT OF NATURAL IMMUNIZING EFFECT OF CHOLERA [J].
CLEMENS, JD ;
VANLOON, F ;
SACK, DA ;
RAO, MR ;
AHMED, F ;
CHAKRABORTY, J ;
KAY, BA ;
KHAN, MR ;
YUNUS, M ;
HARRIS, JR ;
SVENNERHOLM, AM ;
HOLMGREN, J .
LANCET, 1991, 337 (8746) :883-884
[4]   MAGNITUDE, KINETICS, AND DURATION OF VIBRIOCIDAL ANTIBODY-RESPONSES IN NORTH AMERICANS AFTER INGESTION OF VIBRIO-CHOLERAE [J].
CLEMENTS, ML ;
LEVINE, MM ;
YOUNG, CR ;
BLACK, RE ;
LIM, YL ;
ROBINSBROWNE, RM ;
CRAIG, JP .
JOURNAL OF INFECTIOUS DISEASES, 1982, 145 (04) :465-473
[5]   PRACTICAL AND ECONOMICAL METHOD FOR USING BIOTINYLATED DNA PROBES WITH BACTERIAL COLONY BLOTS TO IDENTIFY DIARRHEA-CAUSING ESCHERICHIA-COLI [J].
GICQUELAIS, KG ;
BALDINI, MM ;
MARTINEZ, J ;
MAGGI, L ;
MARTIN, WC ;
PRADO, V ;
KAPER, JB ;
LEVINE, MM .
JOURNAL OF CLINICAL MICROBIOLOGY, 1990, 28 (11) :2485-2490
[6]   EPIDEMIC CHOLERA IN THE AMERICA [J].
GLASS, RI ;
LIBEL, M ;
BRANDLINGBENNETT, AD .
SCIENCE, 1992, 256 (5063) :1524-1525
[7]   SAFETY, IMMUNOGENICITY, AND EXCRETION PATTERN OF SINGLE-DOSE LIVE ORAL CHOLERA VACCINE CVD 103-HGR IN PERUVIAN ADULTS OF HIGH AND LOW SOCIOECONOMIC LEVELS [J].
GOTUZZO, E ;
BUTRON, B ;
SEAS, C ;
PENNY, M ;
RUIZ, R ;
LOSONSKY, G ;
LANATA, CF ;
WASSERMAN, SS ;
SALAZAR, E ;
KAPER, JB ;
CRYZ, S ;
LEVINE, MM .
INFECTION AND IMMUNITY, 1993, 61 (09) :3994-3997
[8]   POTENTIAL FOR REACQUISITION OF CHOLERA ENTEROTOXIN GENES BY ATTENUATED VIBRIO-CHOLERAE VACCINE STRAIN CVD 103-HGR [J].
KAPER, JB ;
MICHALSKI, J ;
KETLEY, JM ;
LEVINE, MM .
INFECTION AND IMMUNITY, 1994, 62 (04) :1480-1483
[9]   PERU-15, AN IMPROVED LIVE ATTENUATED ORAL VACCINE CANDIDATE FOR VIBRIO-CHOLERAE-01 [J].
KENNER, JR ;
COSTER, TS ;
TAYLOR, DN ;
TROFA, AF ;
BARRERAORO, M ;
HYMAN, T ;
ADAMS, JM ;
BEATTIE, DT ;
KILLEEN, KP ;
SPRIGGS, DR ;
MEKALANOS, JJ ;
SADOFF, JC .
JOURNAL OF INFECTIOUS DISEASES, 1995, 172 (04) :1126-1129
[10]   ATTENUATED LIVE CHOLERA VACCINE STRAIN CVD-103-HGR ELICITS SIGNIFICANTLY HIGHER SERUM VIBRIOCIDAL ANTIBODY-TITERS IN PERSONS OF BLOOD-GROUP-O [J].
LAGOS, R ;
AVENDANO, A ;
PRADO, V ;
HORWITZ, I ;
WASSERMAN, S ;
LOSONSKY, G ;
CRYZ, S ;
KAPER, JB ;
LEVINE, MM .
INFECTION AND IMMUNITY, 1995, 63 (02) :707-709